WOOJUNG BIO Inc Asset Resilience Ratio

Latest as of March 2026: 29.05%

WOOJUNG BIO Inc asset resilience ratio. WOOJUNG BIO Inc (215380) has an Asset Resilience Ratio of 29.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 215380 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩35.33 Billion
≈ $23.94 Million USD Cash + Short-term Investments

Total Assets

₩121.62 Billion
≈ $82.42 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of WOOJUNG BIO Inc (2016–2025)

Asset resilience ratio of WOOJUNG BIO Inc from 2016 to 2025. This chart shows how WOOJUNG BIO Inc's Asset Resilience Ratio has changed over time. Read WOOJUNG BIO Inc (215380) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down WOOJUNG BIO Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 215380 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩35.33 Billion 29.05%
Total Liquid Assets ₩35.33 Billion 29.05%

Asset Resilience Insights

  • Very High Liquidity: WOOJUNG BIO Inc maintains exceptional liquid asset reserves at 29.05% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

WOOJUNG BIO Inc Industry Peers by Asset Resilience Ratio

Compare WOOJUNG BIO Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

WOOJUNG BIO Inc Asset Resilience Ratio by Year (2016–2025)

WOOJUNG BIO Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for WOOJUNG BIO Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.33% ₩285.00 Million
≈ $193.14K
₩86.80 Billion
≈ $58.82 Million
+0.07pp
2024-12-31 0.26% ₩248.30 Million
≈ $168.27K
₩94.70 Billion
≈ $64.18 Million
+0.11pp
2023-12-31 0.15% ₩150.00 Million
≈ $101.65K
₩98.33 Billion
≈ $66.64 Million
-4.92pp
2022-12-31 5.07% ₩4.82 Billion
≈ $3.27 Million
₩94.99 Billion
≈ $64.38 Million
-1.66pp
2021-12-31 6.74% ₩6.74 Billion
≈ $4.57 Million
₩100.14 Billion
≈ $67.86 Million
-15.88pp
2020-12-31 22.62% ₩15.79 Billion
≈ $10.70 Million
₩69.82 Billion
≈ $47.31 Million
-3.93pp
2019-12-31 26.55% ₩15.30 Billion
≈ $10.37 Million
₩57.63 Billion
≈ $39.06 Million
-12.30pp
2018-12-31 38.85% ₩17.41 Billion
≈ $11.80 Million
₩44.81 Billion
≈ $30.37 Million
+4.06pp
2017-12-31 34.80% ₩10.93 Billion
≈ $7.40 Million
₩31.40 Billion
≈ $21.28 Million
-64.24pp
2016-12-31 99.04% ₩11.88 Billion
≈ $8.05 Million
₩12.00 Billion
≈ $8.13 Million
--
pp = percentage points

About WOOJUNG BIO Inc

KQ:215380 Korea Biotechnology
Market Cap
$21.84 Million
₩32.22 Billion KRW
Market Cap Rank
#24669 Global
#1778 in Korea
Share Price
₩1933.00
Change (1 day)
-1.02%
52-Week Range
₩1761.00 - ₩3605.00
All Time High
₩13450.00
About

Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and e… Read more